{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:16:52Z","timestamp":1767151012437,"version":"3.48.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s43441-025-00874-z","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:09:56Z","timestamp":1759601396000},"page":"210-222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of Bayesian Borrowing Methods in Clinical Trials for Children with Type II Diabetes Mellitus"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2076-8912","authenticated-orcid":false,"given":"Roberto","family":"Crackel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2630-1967","authenticated-orcid":false,"given":"Yoonhee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6827-7768","authenticated-orcid":false,"given":"James","family":"Travis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenda","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1449-6214","authenticated-orcid":false,"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunghee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9680-6081","authenticated-orcid":false,"given":"Pablo","family":"Bonangelino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"issue":"6","key":"874_CR1","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.2337\/dc13-0707","volume":"36","author":"BL Linder","year":"2013","unstructured":"Linder BL, Fradkin JE, Rodgers GP. The TODAY study: an NIH perspective on its implications for research. Diabetes Care. 2013;36(6):1775\u20136. https:\/\/doi.org\/10.2337\/dc13-0707.","journal-title":"Diabetes Care"},{"issue":"2","key":"874_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1542\/peds.2012-3494","volume":"131","author":"KC Copeland","year":"2013","unstructured":"Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131(2):364\u201382. https:\/\/doi.org\/10.1542\/peds.2012-3494.","journal-title":"Pediatrics"},{"key":"874_CR3","unstructured":"21CFR314.55. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=314.55."},{"key":"874_CR4","unstructured":"Pediatric Research Equity Act. https:\/\/www.fda.gov\/drugs\/development-resources\/pediatric-research-equity-act-prea#:~:text=PREA%20gives%20FDA%20the%20authority,pediatric%20labeling%20for%20the%20product."},{"issue":"7","key":"874_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMoa1903822","volume":"381","author":"WV Tamborlane","year":"2019","unstructured":"Tamborlane WV, Barrientos-P\u00e9rez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1903822.","journal-title":"N Engl J Med"},{"issue":"5","key":"874_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa2204601","volume":"387","author":"SA Arslanian","year":"2022","unstructured":"Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-P\u00e9rez M, et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022;387(5):433\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2204601.","journal-title":"N Engl J Med"},{"issue":"3","key":"874_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2213-8587(22)00387-4","volume":"11","author":"LM Laffel","year":"2023","unstructured":"Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023;11(3):169\u201381. https:\/\/doi.org\/10.1016\/S2213-8587(22)00387-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"874_CR8","unstructured":"Supplemental NDAs 201280\/S-027, 201281\/S-035, 208026\/S-024 Clinical Review. https:\/\/www.fda.gov\/media\/172628\/download"},{"key":"874_CR9","unstructured":"Food and Drug Administration. E11A pediatric extrapolation. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e11a-pediatric-extrapolation."},{"key":"874_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2023.2170405","author":"J Travis","year":"2023","unstructured":"Travis J, Rothmann M, Thomson A. Perspectives on informative Bayesian methods in pediatrics. J Biopharm Stat. 2023. https:\/\/doi.org\/10.1080\/10543406.2023.2170405.","journal-title":"J Biopharm Stat"},{"key":"874_CR11","unstructured":"Food and Drug Administration. E11(R1) addendum: clinical investigation of medicinal products in the pediatric population. 2018. https:\/\/www.fda.gov\/media\/101398\/download."},{"issue":"Supplement 1","key":"874_CR12","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.2337\/dc24-S014","volume":"47","author":"ADAPP","year":"2024","unstructured":"ADAPP. Children and adolescents: standards of care in diabetes\u20142024. Diabetes Care. 2024;47(Supplement 1):S258\u201381. https:\/\/doi.org\/10.2337\/dc24-S014.","journal-title":"Diabetes Care"},{"issue":"1","key":"874_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/jc.2010-1642","volume":"96","author":"KC Copeland","year":"2011","unstructured":"Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96(1):159\u201367.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"874_CR14","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.2337\/dci18-0052","volume":"41","author":"S Arslanian","year":"2018","unstructured":"Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American diabetes association. Diabetes Care. 2018;41(12):2648.","journal-title":"Diabetes Care"},{"key":"874_CR15","unstructured":"VICTOZA product label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022341s044lbl.pdf"},{"key":"874_CR16","unstructured":"BYDUREON Product Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022200s036lbl.pdf"},{"key":"874_CR17","unstructured":"TRULICITY Product Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125469s063lbl.pdf"},{"key":"874_CR18","unstructured":"JARDIANCE Product Label: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204629s040lbl.pdf"},{"key":"874_CR19","unstructured":"FARXIGA Product Label: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/202293s031lbl.pdf"},{"key":"874_CR20","unstructured":"INVOKANA Product Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/204042s043lbl.pdf"},{"key":"874_CR21","unstructured":"BLA 125370\/s-064 and BLA 761043\/s-007 multi-disciplinary review and evaluation benlysta\u00ae (belimumab) for intravenous infusion in children 5 to 17 years of age with SLE. https:\/\/www.fda.gov\/media\/127912\/download."},{"key":"874_CR22","unstructured":"NDA multi-disciplinary review and evaluation {NDA 214070}{Airsupra (budesonide\/albuterol sulfate) metered dose inhaler}. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/214070Orig1s000TOC.cfm."},{"issue":"4","key":"874_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/pst.2299","volume":"22","author":"Y Wang","year":"2023","unstructured":"Wang Y, Tu W, Kim Y, Sinks S, He J, Cambon A, et al. Statistical methods for handling missing data to align with treatment policy strategy. Pharm Stat. 2023;22(4):650\u201370. https:\/\/doi.org\/10.1002\/pst.2299.","journal-title":"Pharm Stat"},{"issue":"1","key":"874_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1740774509356002","volume":"7","author":"B Neuenschwander","year":"2010","unstructured":"Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clin Trials (London, England). 2010;7(1):5\u201318. https:\/\/doi.org\/10.1177\/1740774509356002.","journal-title":"Clin Trials (London, England)"},{"issue":"4","key":"874_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/biom.12242","volume":"70","author":"H Schmidli","year":"2014","unstructured":"Schmidli H, Gsteiger S, Roychoudhury S, O\u2019Hagan A, Spiegelhalter D, Neuenschwander B. Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics. 2014;70(4):1023\u201332. https:\/\/doi.org\/10.1111\/biom.12242.","journal-title":"Biometrics"},{"key":"874_CR26","unstructured":"R\u00f6ver C, Friede T. Meta-analytic-predictive priors based on a single study. 2025. arXiv preprint arXiv:2505.15502."},{"issue":"2","key":"874_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/biom.13252","volume":"76","author":"B Neuenschwander","year":"2020","unstructured":"Neuenschwander B, Weber S, Schmidli H, O\u2019Hagan A. Predictively consistent prior effective sample sizes. Biometrics. 2020;76(2):578\u201387. https:\/\/doi.org\/10.1111\/biom.13252.","journal-title":"Biometrics"},{"issue":"1","key":"874_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/biom.13124","volume":"76","author":"M Wiesenfarth","year":"2020","unstructured":"Wiesenfarth M, Calderazzo S. Quantification of prior impact in terms of effective current sample size. Biometrics. 2020;76(1):326\u201336. https:\/\/doi.org\/10.1111\/biom.13124.","journal-title":"Biometrics"},{"issue":"2","key":"874_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1541-0420.2007.00888.x","volume":"64","author":"S Morita","year":"2008","unstructured":"Morita S, Thall PF, M\u00fcller P. Determining the effective sample size of a parametric prior. Biometrics. 2008;64(2):595\u2013602. https:\/\/doi.org\/10.1111\/j.1541-0420.2007.00888.x.","journal-title":"Biometrics"},{"key":"874_CR30","doi-asserted-by":"crossref","unstructured":"Zhang H, Anderson KM, Zimmer Z, Golm G, Sapre A, Ibrahim JG.. Prior Effective sample size when borrowing on the treatment effect scale. 2024. arXiv preprint arXiv:2404.13366.","DOI":"10.1002\/sim.70235"},{"key":"874_CR31","unstructured":"JANUMET Product Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022044s052lbl.pdf"},{"key":"874_CR32","unstructured":"JANUMET XR Product Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/202270s026lbl.pdf"},{"issue":"4","key":"874_CR33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/cpt.1723","volume":"107","author":"H Schmidli","year":"2020","unstructured":"Schmidli H, H\u00e4ring DA, Thomas M, Cassidy A, Weber S, Bretz F. Beyond randomized clinical trials: use of external controls. Clin Pharmacol Ther. 2020;107(4):806\u201316. https:\/\/doi.org\/10.1002\/cpt.1723.","journal-title":"Clin Pharmacol Ther"},{"key":"874_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2022.2162069","author":"A Majumdar","year":"2023","unstructured":"Majumdar A, Rothwell R, Reaman G, Ahlberg C, Roy P. Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: a pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL). J Biopharm Stat. 2023. https:\/\/doi.org\/10.1080\/10543406.2022.2162069.","journal-title":"J Biopharm Stat"},{"key":"874_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2022.2149772","author":"B Sebastien","year":"2022","unstructured":"Sebastien B, Cheung SA, Corriol-Rohou S, Gamalo-Siebers M, Jreich R, Krishna R, et al. Use of pharmacodynamic modeling for Bayesian information borrowing in pediatric clinical trials. J Biopharm Stat. 2022. https:\/\/doi.org\/10.1080\/10543406.2022.2149772.","journal-title":"J Biopharm Stat"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00874-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00874-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00874-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:04:08Z","timestamp":1767150248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00874-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00874-z","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"type":"print","value":"2168-4790"},{"type":"electronic","value":"2168-4804"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}